Covid Vaccine Race

A survey published in JAMA reveals some remain firmly entrenched.

The Biden administration is also setting mandates for health care workers in facilities receiving federal aid.

Novavax was approved for their first COVID-19 vaccine EUA in Indonesia, and expects more to follow shortly.

The ACIP considered the benefits of the newly emergency-authorized vaccine versus the risks of COVID-19 in children aged 5-11 years old.

Loma Linda University worked with local leaders to help promote equitable delivery of COVID-19 vaccines in Black communities.

Pilot program benefits those in need most, covering potential costs associated with vaccination.

The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.

The latest National Immunization Survey-Child, for children born in 2017- 2018, reveals different rates of vaccination by demographic and disease.

A new study assessed the vaccine acceptance and access among Black and Latinx communities.

This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

Booster dose eligibility is broadening as the flu season approaches. An expert emphasizes the need to protect for both COVID-19 and the flu in the coming months.

Investigators retrospectively observed 2 communities of essential workers in Toronto, Canada.

Unpublished data from the company's ongoing pediatric trial show children aged 6 to <12 years old have an antibody response greater than that of young adults.

Data presented to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) showed 2 10 µg doses of the Pfizer-BioNTech vaccine to be 90.7% effective in children older than 5 and younger than 12.

The FDA and CDC have authorized and recommended 3 different booster doses, to be used in "mix-and-match" strategy among eligible adults. What does this mean for immunity?

The Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky's, MD, endorsement Thursday evening came after 2 days of deliberation from the CDC’s Advisory Committee on Immunization Practices (ACIP) where the group recommended the Moderna and Janssen COVID-19 vaccine “booster” doses.

The actions taken by the FDA set differing availability of the 3 emergency-authorized vaccines.

The CDC found 2 doses of Pfizer-BioNTech reduced COVID-19 severe outcomes and hospitalization by 93% in adolescents 12-18 years old.

The White House said it has secured enough of the Pfizer-BioNTech vaccine supply to offer vaccinations for everyone in this age group.

The decision comes after supporting data from a "mix and match" trial last week, and may align with emergency authorizations for the Moderna and Janssen booster doses.

The VRBPAC committee unanimously voted in favor of the Janssen (Johnson & Johnson) COVID-19 vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination.

Lower rates of COVID-19 vaccination may be due to access, not hesitancy.

The VRBPAC meeting precedes deliberation from the FDA on amending the company's emergency authorization to include booster doses for adult patients.

While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.

The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.

New clinical trial is first to describe concomitant administration of any vaccine with either an adenoviral vector or mRNA COVID-19 vaccine.

In the recent TACKLE phase 3 trial, AZD7442 significantly reduced the risk of developing severe COVID-19 or death, even among high-risk populations.

The companies made the request after their recent submission of data to support the emergency use authorization (EUA) in this patient population.